Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events
- PMID: 39356977
- PMCID: PMC12172021
- DOI: 10.1200/JCO-24-01570
Role for Artificial Intelligence in the Detection of Immune-Related Adverse Events
Abstract
In the article that accompanies this editorial, Sun and colleagues utilized large language models (LLMs) to detect immune-related adverse events (irAEs) from electronic health records and demonstrated that LLMs had higher sensitivity than ICD codes alone (94.7% vs 68.7% respectively) and similar specificity, requiring a fraction of the time compared to manual adjudication. This research represents a significant step in enhancing the efficiency of our efforts to better understand irAEs by leveraging data in the electronic medical records from patients treated with immune checkpoint inhibitors over the last 15 years to better predict these toxicities, with the goal of minimizing or mitigating them entirely.
References
-
- Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. Mar 2022;86(3):563–572. doi: 10.1016/j.jaad.2021.03.094 - DOI - PMC - PubMed
-
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Jun 10 2018;36(17):1714–1768. doi: 10.1200/jco.2017.77.6385 - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
